左心房与左心室放疗剂量可预测乳腺癌放疗后长期心血管事件
该回顾性研究纳入2007–2008年单侧乳腺癌术后放疗患者878例,中位随访16.5年,173例发生MACE并与167例对照匹配。结果显示左心房最大剂量与MACE、新发心衰、房颤及瓣膜病相关,左心室平均剂量与冠心病相关,而平均心脏剂量与毒性无关。
要点
- 左心房最大放疗剂量与MACE、新发心衰、房颤及瓣膜病相关。
- 左心室平均放疗剂量与冠心病发生相关。
- 平均心脏剂量与心血管毒性无显著关联。
核心结论
- 乳腺癌放疗后长期随访可出现多种心血管毒性。
- 左侧心脏亚结构受照剂量较高与特定心血管终点相关。
- 平均心脏剂量与毒性无关联。
研究设计与样本
- 回顾性研究纳入2007–2008年诊断的单侧乳腺癌女性患者,均在匿名中心接受放疗。
- 878例患者中173例发生MACE并与167例对照按心血管危险因素、蒽环类及抗HER2治疗匹配。
- 在模拟扫描上勾画心脏亚结构,采用多变量逻辑回归评估放疗剂量与MACE或其他心血管事件的关联。
主要发现
- 中位随访16.5年(IQR 16.1–17.1),新发房颤98/878(11.16%)、心衰82/878(9.34%)、冠心病46/878(5.24%)、瓣膜病180/878(20.50%)。
- MACE组平均心脏剂量6.62±5.20Gy,对照组5.76±4.96Gy(p=0.0916)。
- 与对照组相比,MACE患者疾病分期更高且冠心病、房颤和心衰病史更常见。
- 左心房最大放疗剂量与MACE、新发心衰、房颤及瓣膜病相关(均p<0.05)。
- 左心室平均放疗剂量与冠心病发生相关(p<0.05)。
关键数值与推荐
- 所有患者接受三维适形放疗,总剂量50 Gy分25次,可伴瘤床加量。
- 左心房最大剂量与MACE、新发心衰、房颤及瓣膜病相关(均p<0.05)。
- 左心室平均剂量与冠心病相关(p<0.05)。
- 平均心脏剂量与毒性无关联。
临床怎么用
- 乳腺癌放疗计划评估时可关注左心房最大剂量与左心室平均剂量。
- 对左侧心脏亚结构受照剂量较高的患者加强长期心血管随访。
- 平均心脏剂量不足以单独预测长期心血管毒性。
局限性
- 为单中心回顾性研究,可能存在选择偏倚。
- MACE与对照按心血管危险因素及全身治疗匹配,但组间疾病分期与病史仍存在差异。
- 原文未报告多变量模型的具体校正变量与效应值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant breast cancer (BC) radiotherapy (RT) improves survival and local control, but cardiovascular (CV) toxicity remains a concern. AIM: This retrospective study investigated the association between RT doses to cardiac substructures and CV toxicity 15 years after BC RT. METHODS: Women with unilateral BC diagnosed between 2007 and 2008, treated with RT at [Anonymous] were retrospectively included. Patients with major adverse cardiac events (MACE) were matched to controls by CV risk factors, anthracycline and anti-HER2 therapy. Cardiac substructures were delineated on simulation scans, and multivariable logistic regression was performed to assess associations between RT doses to these substructures and MACE or other CV events. RESULTS: After a median follow-up of 16.5 years (IQR 16.1-17.1), and inclusion of 878 patients, 173 patients experienced MACE and were matched to 167 controls. All patients underwent adjuvant RT using 3-dimensional conformal RT to a total dose of 50 Gy in 25 fractions, with or without a boost to the tumor bed. New individual cardiac toxicities included: atrial fibrillation (AF) 98/878 (11.16%), heart failure (HF) 82/878 (9.34%), coronary artery disease (CAD) 46/878 (5.24%) and valvular disease 180/878 (20.50%). Mean heart doses were 6.62 ± 5.20Gy (MACE) and 5.76 ± 4.96Gy (controls) (p = 0.0916). Compared with controls, patients with MACE had significantly higher disease stage and more frequent histories of CAD, AF and HF. Maximum RT doses to the left atrium (LA) were associated with MACE, new-onset HF, AF and valvular disease, while mean RT dose to the left ventricle (LV) was associated with development of CAD (all p < 0.05). CONCLUSION: This study demonstrates that patients treated with RT for BC may experience diverse CV toxicities during long-term follow-up. Higher doses to left-sided cardiac substructures, particularly the LA and LV, were associated with specific CV endpoints, while MHD was not associated with toxicity.
引用
- Van der Vorst A, Jacobs J, Van Lerberghe R, et al. Left atrial and left ventricular radiation exposure predict long-term cardiovascular events after breast cancer radiotherapy. Clin Transl Radiat Oncol. 2026. PMID: 42904112. doi:10.1016/j.ctro.2026.101313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。